Affimed signs $96M deal with Genentech to develop new cancer drug

Date: 2018-08-28   Author: Pankaj Singh  Category: #news

Affimed signs $96M deal with Genentech to develop new cancer drug

Affimed N.V., has reportedly secured a $96 million investment and an opportunity to collaborate with the research team at Genentech. The collaboration is speculated to help Affimed develop an NK and T cell immunotherapies targeted towards multiple kinds of cancer.

Sources claim that the biotech firm may receive an additional $5.0 billion funding as milestone payments and royalties on sales. The collaboration with Genentech, which is a member of the Roche Group will focus on developing and commercializing Affimed’s new immunotherapeutics to treat cancer.

Based on the agreement, Affimed will discover an advanced and innate immune cell engager based immunotherapeutic focused on some goals Genentech has in mind. Affimed will direct its proprietary Redirected Optimized Cell Killing (ROCK), which helps produce T cell-engaging antibodies and NK cell, to help Affimed in developing the treatment for Genentech.

The collaboration will also include candidate products developed through Affimed’s ROCK platform and undisclosed hematologic tumor targets. The agreement will seemingly span multiple stages, right from discovery to late-stage research phases, reported sources.

Dr. Adi Hoess, Affimed’s CEO was quoted saying that Affimed is pleased to work with a company with proven expertise in oncology and excellence in generating cancer medication. He further addressed that the partnership is part of a strategy to explore the full potential of innate immune cells in oncology.

According to sources familiar with the matter, James Sabry, Global Head of Partnering at Roche Pharma, claimed that this partnership is a result of Affimed’s discovery of the innate immune cell drug and Genentech’s profound understanding of cancer immunology. The collaboration with Affimed provides an opportunity to improvise Roche’s efforts to understand the ways in which the immune system can be activated in order to combat cancer, he further commented.

Incidentally, Genentech will head the process of clinical development and commercialization of the product worldwide, claim reports.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Hard Disk Drive Market Development, Growth, Trends, Demand, Share, Analysis and Forecast 2026

Author: Ashwin Naphade

A recent research on ' Hard Disk Drive market', now available with Market Study Report, LLC, is a thorough study on the latest market trends prevailing in the global business sphere. The report also offers important details pertaining to market sh...


Service Delivery Platform Market with manufacturers, Application, regions and SWOT Analysis 2026

Author: Ashwin Naphade

Market Study Report, LLC, has added a research study on ' Service Delivery Platform market' which delivers a concise outline of the market share, market size, revenue estimation, geographical outlook and SWOT analysis of the business. The ...


Shower Heads and Systems Market Analysis: Global Industry Trends, Share, Key Players, Size, Forecast to 2026

Author: Ashwin Naphade

Market Study Report, LLC, now offers a research study on ' Shower Heads and Systems market' which offers a precise outline of the industry valuation, SWOT Analysis, market size, revenue estimation and the geographical outlook of the business. The ...